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Objectives: Invasive fungal infections are a major cause of mortality among patients at risk. Treatment
guidelines vary on optimal treatment strategies. We aimed to determine the effects of different antifungal
therapies on global response rates, mortality and safety.
Methods: We searched independently and in duplicate 10 electronic databases from inception to May
2009. We selected any randomized trial assessing established antifungal therapies for confirmed cases of
invasive candidiasis among predominantly adult populations. We performed a meta-analysis and then
conducted a Bayesian mixed treatment comparison to differentiate treatment effectiveness. Sensitivity
analyses included dosage forms of amphotericin B and fluconazole compared to other azoles.
Results: Our analysis included 11 studies enrolling a total of 965 patients. For our primary analysis of
global response rates, we pooled 7 trials comparing azoles to amphotericin B, Relative Risk [RR] 0.87 (95%
Confidence Interval [CI], 0.78–0.96, P = 0.007, I2 = 43%, P = 0.09. We also pooled 2 trials of echinocandins
versus amphotericin B and found a pooled RR of 1.10 (95% CI, 0.99–1.23, P = 0.08). One study compared
anidulafungin to fluconazole and yielded a RR of 1.26 (95% CI, 1.06–1.51) in favor of anidulafungin. We
pooled 7 trials assessing azoles versus amphotericin B for all-cause mortality, resulting in a pooled RR of
0.88 (95% CI, 0.74–1.05, P = 0.17, I2 = 0%, P = 0.96). Echinocandins versus amphotericin B (2 trials) for all-
cause mortality resulted in a pooled RR of 1.01 (95% CI, 0.84–1.20, P = 0.93). Anidulafungin versus
fluconazole resulted in a RR of 0.73 (95% CI, 0.48–1.10, P = 0.34). Our mixed treatment comparison
analysis found similar within-class effects across all interventions. Adverse event profiles differed, with
amphotericin B exhibiting larger adverse event effects.
Conclusion: Treatment options appear to offer preferential effects on response rates and mortality.
When mycologic data are available, therapy should be tailored.
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Introduction
Invasive fungal infections contribute importantly to mor-
bidity and mortality in immunocompromised patients
including those with hematologic cancers, recent trans-
plants, autoimmune disorders, and critical illness. The
most common fungal pathogen is Candida.
For a number of reasons, early and accurate diagnosis of
invasive fungal infections is often difficult and patients
from these high risk groups may have evidence of dissem-
inated fungal infection at autopsy that was not identified
prior to death[1]. Clinical manifestations of invasive fun-
gal infections often occur at a late stage of infection con-
tributing to diagnostic delays and higher case-fatality
rates. Immunocompromised patients may not generate
detectable antibody responses to specific fungal patho-
gens[2]. Furthermore, non-invasive antigen detection
methods such as the Fungitec G assay for beta-1–3 glucan
are not widely available. Finally, culture techniques are
not highly sensitive, and invasive diagnostic techniques
may be contraindicated or not applicable to the clinical
presentation. Consequently, antifungal treatment for con-
firmed invasive fungal infections is challenging and eval-
uations of therapeutic interventions are limited[3].
Several choices of antifungal agents exist that differ greatly
with respect to both toxicity and cost[4].
There is an ever-growing literature on the use of antifungal
agents in patients with candidemia. Previous systematic
reviews have not looked at the relative effectiveness of
interventions of confirmed infections [4-6]. Using a sys-
tematic review of the literature and meta-analytic tech-
niques, we aimed to quantify the effects of antifungal
therapy on confirmed systemic fungal infection response
rates, associated mortality and safety when reserved for
confirmed cases only. Furthermore, we determined differ-
ences in treatment effects across interventions using a
mixed treatment comparison meta-analysis.
Methods
Eligibility criteria
We included any randomized trial of antifungal therapies
for confirmed cases of invasive candidiasis among pre-
dominantly adult (³ 18 years of age) populations. We
included randomized trials of any duration. Given that
head to head evaluations have existed for decades, studies
had to compare antifungal therapy to another antifungal
therapy (head-to-head evaluations). Studies had to report
on any of the following clinically-important outcomes:
clinical response, all-cause mortality; fungal-attributable
death, and adverse events. We excluded studies only
reporting on dose-comparison or dosage form evalua-
tions. As we were interested in disseminated disease, trials
focused on single site fungal infections (mucocutaneous,
esophageal, dermatologic, meningeal, bladder, or focal
chest) were excluded, as were aspergillosis trials, crypto-
coccosis and endemic mycoses trials. We excluded drugs
no longer recommended by Infectious Disease Society of
America Guidelines (IDSA) including ketoconazole[7].
Search strategy
In consultation with a medical librarian, we (DP, EM)
established a search strategy (available from correspond-
ing author on request). We searched independently, in
duplicate, the following 10 databases (from inception to
May 2009): MEDLINE, EMBASE, Cochrane CENTRAL,
AMED, CINAHL, TOXNET, Development and Reproduc-
tive Toxicology, Hazardous Substances Databank, Psych-
info and Web of Science, databases that included the full
text of journals (OVID, ScienceDirect, and Ingenta, includ-
ing articles in full text from approximately 1700 journals
since 1993). Key search words included words addressing
the infections: Fungus, fungal, fungemia, mycosis, candidia-
sis, candidemia, candida; and words addressing the interven-
tions: antifungal, amphotericin, azoles, triazoles, fluconazole,
itraconazole, miconazole, voriconazole, posaconazole, ravuco-
nazole, flucytosine, echinocandins, caspofungin, micafungin,
anidulafungin, confirmed; and finally a word indicating a
randomized trial: random* (wildcard). In addition, we
searched the bibliographies of published systematic
reviews and collected papers. We contacted the authors of
trials for study clarifications, where required. Searches
were not limited by language, sex or age.
Study selection
Two investigators (DP, EM) working independently, in
duplicate, scanned all abstracts and obtained the full-text
reports of records, that indicated or suggested that the
study was a randomized trial evaluating antifungal ther-
apy on the outcomes of interest. After obtaining full
reports of the candidate trials, in full peer-reviewed publi-
cation, the same reviewers independently assessed eligi-
bility from full text papers.
Data collection
The same 2 reviewers conducted data extraction inde-
pendently using a standardized pre-piloted form. Review-
ers collected information about the antifungal therapy
and type of interventions tested, the population studied
(age, setting, underlying conditions), the treatment effect
on specified outcomes, adverse events, and specific
adverse events addressing renal toxicity and liver impair-
ment. Study evaluation included general methodological
quality features, including allocation concealment,
sequence generation, a description of who was blinded,
use of intention-to-treat analysis and proportion of study
population lost-to-follow-up. We entered the data into an
electronic database such that duplicate entries existed for
each study; when the two entries did not match, we
resolved differences through discussion and consensus.Annals of Clinical Microbiology and Antimicrobials 2009, 8:23 http://www.ann-clinmicrob.com/content/8/1/23
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Data analysis
In order to assess inter-rater reliability on inclusion of arti-
cles, we calculated the Phi statistic, that provides a meas-
ure of inter-observer agreement independent of
chance[8]. Our primary outcome of interest is response
rates. Secondary outcomes include all-cause mortality,
fungal-attributable mortality, and adverse events.
We performed two specific analyses. First, we performed a
frequentist fixed-effects meta-analysis of study outcomes
across classes of drugs, applying a Relative Risk [RR] and
appropriate 95% Confidence Intervals [CIs] of outcomes
according to the number of events reported in the original
studies. In the event of zero outcome events in one arm of
a trial, we used the Haldane method and added 0.5 to
each arm[9]. Given the varied size of studies, we pooled
studies using a fixed effects approach that recognizes the
precision of studies and provides greater to weight to
larger studies[10]. We calculated the I2 statistic for each
analysis as a measure of the proportion of the overall var-
iation that is attributable to between-study heterogene-
ity[11]. Given the varied interventions, and the
consideration that most trials were not no-treatment or
placebo controlled, we pooled studies assessing within-
class interventions as head-to-head trials. Our first analy-
sis examined drugs within-class and then examined indi-
vidual drugs using the mixed treatment comparisons. We
initially pooled all azole interventions versus all ampho-
tericin B trials for response and conducted a multivariable
meta-regression using the unrestricted maximum likeli-
hood method assessing the impact of individual azoles on
the overall estimate of effect and the individual delivery
methods of amphotericin B on overall estimate[12]. Our
regression covariates were chosen a priori and included:
amphotericin delivery and allocation concealment. Anal-
yses were conducted using StatsDirect and STATA.
For our second analysis, we examined the relative effec-
tiveness of each individual drug using the Lu-Ades fixed
effects method for combining direct and indirect evidence
in mixed treatment comparisons, a Bayesian
approach[13]. We estimated the posterior densities for all
unknown parameters using MCMC (Markov chain Monte
Carlo) for each model in WinBUGS version 1.4 (Medical
Research Council Biostatistics Unit, Cambridge). Each
chain used 100,000 iterations with a burn-in of 500, thin
of 5, and updates varying between 80 and 110. We used
the same seed number (SEED = 314159) for all chains.
The choice of burn-in was chosen according to Gelman-
Rubin approach[14]. We assessed convergence based on
trace plots and time series plots (available upon request).
The accuracy of the posterior estimates was done by calcu-
lating the Monte Carlo error for each parameter. As a rule
of thumb, the Monte Carlo error for each parameter of
interest is less than about 5% of the sample standard devi-
ation[15]. All results are reported as posterior means with
corresponding 95% credibility intervals (CrIs). Credibility
intervals are the Bayesian equivalent of classical confi-
dence intervals.
Results
Our literature search identified 1284 potentially relevant
abstracts of full text articles. Of these, 42 full text RCTs
were obtained. We excluded 31, leaving 11 that met our
Flow-diagram of search and included studies Figure 1
Flow-diagram of search and included studies.Annals of Clinical Microbiology and Antimicrobials 2009, 8:23 http://www.ann-clinmicrob.com/content/8/1/23
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Global response rate fixed-effects meta-analysis: Triazoles versus amphotericin B Figure 2
Global response rate fixed-effects meta-analysis: Triazoles versus amphotericin B.
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combined [fixed] 0.87 (0.78, 0.96)
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All-cause mortality fixed-effects meta-analysis: Triazoles versus amphotericin B Figure 3
All-cause mortality fixed-effects meta-analysis: Triazoles versus amphotericin B.
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inclusion criteria[2,3,16-24], Phi = 0.91, n = 2,554, See
Figure 1 and Additional File 1. The majority (n = 7) of
studies assessed the head-to-head non-inferiority of azole-
class drugs compared to amphotericin B. The azoles
include fluconazole[2,3,17,18,23], itraconazole[16], and
voriconazole[19]. The other studies assessed anidulafun-
gin to fluconazole[22], micafungin to amphotericin
B[20]; caspofungin to amphotericin B[21];and micafun-
gin to caspofungin[24]. Trials were predominantly con-
ducted in populations dominated by patients with
hematologic cancers experiencing infection with Candida
species. The median participant age was 57 years (IQR 56–
59).
In keeping with the time periods that the studies were
published (1991–2007), reporting of study methodologi-
cal features was moderate. Seven of eleven trials reported
on sequence generation; 6 of 11 on allocation conceal-
ment; 3 of 11 on who was blinded; 9 of 11 reported using
intent-to-treat principles; and 6 of 11 provided details on
participants lost-to-follow-up. An average of 10.8% of
study participants were lost-to-follow-up.
Meta-analysis
Global response rates
For our primary outcome, we pooled 7 trials (n = 965, See
Figure 2) assessing azoles to amphotericin B. Our pooled
estimate is 0.87 (95% CI, 0.78-0.96, P = 0.007, I2 = 43%,
P = 0.09). When we compared only fluconazole trials (5
trials) to amphotericin B, we found similar effects (RR
0.82, 95% CI, 0.74–0.92, P = 0.0009, I2 = 52%, P = 0.07).
The itraconazole versus amphotericin B trial (RR 0.90,
95% CI, 0.49–1.63, P = 0.61) and voriconazole versus
amphotericin B trial (RR 0.99, 95% CI, 0.77–1.30, P =
0.94) provided similar estimates.
We also pooled 2 trials of echinocandins (micafungin[20]
and caspofungin[21]) versus amphotericin B and found a
Table 1: Odds ratios and 95% CrIs for mixed treatment comparisons of confirmed infection studies, Response rates
Treatment Comparison Odds Ratio 95% Credible Interval
Caspofungin vs. Fluconazole 2.03 (0.98, 3.76)
Amphotericin B Deoxycholate vs. Fluconazole 1.13 (0.78, 1.58)
Amphotericin B Liposomal vs. Fluconazole 1.85 (0.65, 4.19)
Voriconazole vs. Fluconazole 1.14 (0.62, 1.94)
Micafungin vs. Fluconazole 2.13 (0.83, 4.55)
Anidulafungin vs. Fluconazole 2.14 (1.19, 3.58)
Itraconazole vs. Fluconazole 1.97 (0.32, 6.69)
Amphotericin B Deoxycholate vs. Caspofungin 0.60 (0.32, 1.02)
Amphotericin B Liposomal vs. Caspofungin 0.91 (0.45, 1.63)
Voriconazole vs. Caspofungin 0.61 (0.27, 1.18)
Micafungin vs. Caspofungin 1.04 (0.59, 1.70)
Anidulafungin vs. Caspofungin 1.18 (0.45, 2.56)
Itraconazole vs. Caspofungin 1.05 (0.16, 3.72)
Amphotericin B Liposomal vs. Amphotericin B Deoxycholate 1.64 (0.63, 3.52)
Voriconazole vs. Amphotericin B Deoxycholate 1.01 (0.63, 1.54)
Micafungin vs. Amphotericin B Deoxycholate 1.88 (0.80, 3.79)
Anidulafungin vs. Amphotericin B Deoxycholate 1.96 (0.96, 3.58)
Itraconazole vs. Amphotericin B Deoxycholate 1.74 (0.30, 5.77)
Voriconazole vs. Amphotericin B Liposomal 0.75 (0.25, 1.74)
Micafungin vs. Amphotericin B Liposomal 1.18 (0.81, 1.68)
Anidulafungin vs. Amphotericin B Liposomal 1.44 (0.42, 3.66)
Itraconazole vs. Amphotericin B Liposomal 1.28 (0.16, 4.86)
Micafungin vs. Voriconazole 1.95 (0.72, 4.31)
Anidulafungin vs. Voriconazole 2.03 (0.85, 4.13)
Itraconazole vs. Voriconazole 1.81 (0.28, 6.22)
Anidulafungin vs. Micafungin 1.21 (0.38, 2.94)
Itraconazole vs. Micafungin 1.08 (0.14, 3.99)
Itraconazole vs. Anidulafungin 0.99 (0.14, 3.56)Annals of Clinical Microbiology and Antimicrobials 2009, 8:23 http://www.ann-clinmicrob.com/content/8/1/23
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pooled RR of 1.10 (95% CI, 0.99–1.23, P = 0.08). The ani-
dulafungin to fluconazole trial yielded a RR of 1.26 (95%
CI, 1.06–1.51, P = 0.001) in favor of anidulafungin[22];
and micafungin to caspofungin (RR 1.00, 95% CI, 0.94–
1.08, P = 0.21)[24].
All-cause mortality
Our secondary outcomes included all-cause mortality. We
pooled 7 trials (n = 965, figure 3) assessing azoles versus
amphotericin B for all-cause mortality, resulting in a
pooled RR of 0.88 (95% CI, 0.74–1.05, P = 0.17, I2 = 0%,
P = 0.96). This was also found when individual azoles
were analyzed: fluconazole (5 trials) RR 0.92 (95% CI,
0.73–1.17, P = 0.51, I2 = 0%, P = 0.90; itraconazole (1 tri-
als) RR 0.67, 95% CI, 0.74–1.05, P = 0.20; voriconazole (1
trials) RR 0.85, 95% CI, 0.65–1.12, P = 0.67).
When we assessed echinocandins versus amphotericin B
preparations (2 trials) for all-cause mortality, we found a
pooled RR of 1.01 (95% CI, 0.84–1.20, P = 0.93).
Micafungin versus caspofungin resulted in a RR of 0.85
(95% CI, 0.96–1.11) in the direction of favour of caspo-
fungin. Anidulafungin versus fluconazole resulted in a RR
of 0.73 (95% CI, 0.48–1.10, P = 0.34) in the direction of
anidulafungin.
Fungal-attributable mortality
We also assessed deaths attributable to the fungal infec-
tions. When we pooled 5 azole trials versus amphotericin
B, we found a pooled RR of 0.84 (95% CI, 0.49–1.42, P =
0.51, I2 = 0%, P = 0.74). When we pooled the 3 echinoc-
andin trials versus amphotericin B, we found a pooled RR
of 1.16 (95% CI, 0.75–1.79, P = 0.50). Anidulafungin ver-
sus fluconazole yielded a RR of 0.84 (95% CI, 0.48–1.47,
P = 0.88).
Adverse events
To assess serious adverse events, we pooled 2 trials of
azoles versus amphotericin B assessing serious adverse
events and found a pooled RR of 0.67 (95% CI, 0.55–
0.81, P = <0.0001) in favour of azoles. We also pooled 2
trials of echinocandins versus amphotericin B and found
Network of evidence formed by the eight antifungal treatments compared on the basis of mortality data from 11 studies Figure 4
Network of evidence formed by the eight antifungal treatments compared on the basis of mortality data from 
11 studies. Each treatment is a node in the network. The links between nodes are trials or pairs of trial arms. The numbers 
along the link lines indicate the number of trials or pairs of trial arms for that link in the network.
A
G
C
D B
E
H
F
A = Fluconazole
B = Caspofungin 
C = Amphotericin B Deoxycholate 
D = Amphotericin B Liposomal
E = Voriconazole
F = Micafungin
G = Anidulafungin
H = Itraconazole
1
5
1
1
1
11
Table 2: Absolute treatment efficacy and the probability that 
each treatment is best in the mixed treatment comparisons 
analysis using the response data from the confirmed infection 
studies.
Response Rates
Response % Probability best
Fluconazole 63.00 0.000
Caspofungin 76.10 0.139
Amphotericin B Deoxycholate 65.40 0.000
Amphotericin B Liposomal 72.98 0.070
Voriconazole 65.03 0.004
Micafungin 75.98 0.200
Anidulafungin 77.49 0.345
Itraconazole 69.33 0.241Annals of Clinical Microbiology and Antimicrobials 2009, 8:23 http://www.ann-clinmicrob.com/content/8/1/23
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a pooled RR of 0.49 (95% CI, 0.37–0.66, P = <0.0001) in
favour of the echinocandins. Micafungin and caspofungin
were not dissimilar in their safety profiles (RR 0.94, 95%
CI, 0.70–1.29). We found no significant difference
between anidulafungin versus fluconazole (RR 0.90, 95%
CI, 0.60–1.36, P = 0.66).
When we assessed nephrotoxicity defined variably accord-
ing to the different studies, we pooled 6 trials of azoles
compared to amphotericin B. We found a pooled RR of
0.22 (95% CI, 0.15–0.32, P = <0.0001, I2 = 74%, P =
0.001) in favour of azoles. We also pooled 3 echinocan-
din compared to amphotericin trials and found a pooled
RR 0.31 (95% CI, 0.17–0.57).
Finally, we assessed hepatic enzyme elevations beyond
normal. We pooled 3 trials assessing azoles compared to
amphotericin B and found a pooled RR of 1.08 (95% CI,
0.79–1.47, P = 0.64, I2 = 0%, P = 0.63). The 2 echinocan-
din versus amphotericin B trials yielded a pooled RR of
1.03 (95% CI, 0.17–6.26). The single anidulafungin ver-
sus fluconazole trial found a RR of 0.21 (95% CI, 0.05–
0.83, P = 0.001) in favour of anidulafungin.
Mixed treatment comparisons
Figure 4 displays the geometric distribution of the mixed
treatment comparison. Figures 5 and 6 display the cater-
pillar plots. Table 1 reports the odds ratios of response
rates for all the pairwise comparisons of the antifungal
treatment regimens and table 2 presents estimates of the
absolute efficacy for each treatment, along with the esti-
mated probability that each treatment is best (response
rate).
Table 3 reports the odds ratios of all-cause mortality for all
the pairwise comparisons of the antifungal treatment reg-
imens and table 4 presents estimates of the absolute effi-
cacy for each treatment, along with the estimated
probability that each treatment is best (mortality).
Discussion
The results of our systematic review and meta-analysis
should be of interest to clinicians, policy-makers and
patient groups. Our study found similar effects across
within-class interventions. Safety profiles indicate that the
class of interventions, azoles and echinocandins, offer
protection over amphotericin B in terms of adverse events.
Caterpillar plots of the odds ratios and 95% CrIs for mixed treatment comparisons, response rates Figure 5
Caterpillar plots of the odds ratios and 95% CrIs for mixed treatment comparisons, response rates.
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There are several important strengths to our meta-analyses
that should be considered when interpreting this study.
We used extensive searching of electronic databases to
identify studies. Thus, we identified more studies than any
other systematic reviews[4,5,25]. In order to reduce bias,
we conducted our searches independently, in duplicate.
We extensively searched the bibliographies of published
trials and reviews in order to identify unpublished or
obscure papers. Finally, we used methodologically
advanced approaches to pool and conducted sensitivity
analyses across a priori defined covariates.
There are also several limitations to consider when inter-
preting our analysis. Despite our extensive searching, it is
possible that we were unable to identify unpublished tri-
als. Indeed, this issue affects every meta-analysis. We
attempted contact through email with 12 study authors to
address inclusion and methodological questions but
received responses from only 4; a common occurrence
with systematic reviews [26]. We examined 3 major clini-
cal outcomes and their sub-categories: global response,
mortality and adverse events. It is possible that other out-
comes would yield differing effects. We conducted mixed
treatment comparisons and demonstrated similar within-
class effects of drugs. These comparisons provide compel-
ling comparisons, but only head-to-head trials will pro-
vide stronger inferences[27,28].
We considered response according to the original papers'
definition of response. We considered response according
to the original papers' definition of response. Notably,
there is substantial variability in the timing and defini-
tions of response across trials which may limit compara-
bility. Timing of assessments ranged from 7 days after start
of therapy[2] to up to 12 weeks after the end of ther-
apy[19], with multiple variations in between. The criteria
for response also included a wide variety of clinical and
microbiological response definition, as well as considera-
tion of the ability to tolerate randomized ther-
apy[2,21,23]. However, we feel our analysis is useful and
as we saw no evidence of discrepancies based on our sen-
sitivity analysis. More similarity in endpoint definitions in
future trials would be useful to facilitate across-trial com-
parisons and evaluation of future therapies.
There has been an ongoing debate over the quality of
industry-funded trials of antifungal agents, predomi-
nantly in the empiric and prophylaxis trials [29-31]. This
Caterpillar plots of the odds ratios and 95% CrIs for mixed treatment comparisons, all-cause mortality Figure 6
Caterpillar plots of the odds ratios and 95% CrIs for mixed treatment comparisons, all-cause mortality.
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contention has predominantly concerned clarifications
post-publication, the use of oral amphotericin B com-
pared to intravenous, and the reporting of all-cause mor-
tality compared to cause-specific mortality. In our analysis
we have aimed to overcome this discussion through
extensive sensitivity analysis, through focusing on con-
firmed fungal infections, through evaluating relative effec-
tiveness and through presenting both all-cause and cause-
specific mortality.
A conundrum in evaluating antifungal therapy is assessing
fungle attributable mortality. In most trials, the patients
enrolled were at a high risk of mortality due to illness.
When we assess all-cause mortality, we recognize that
many of the patients would have died from their original
disease and not fungal infections. Clinical practice may
differ from clinical trial procedures as clinicians may
reserve more toxic agents (amphotericin B) for salvage
therapy of more severely ill patients who failed short
courses of other therapies. However, we could not display
a difference between these drug classes when we exam-
ined deaths attributable to fungal infections.
We examined the impact of different dosage forms of
amphotericin B to determine if their results change and
found it did not. A prior systematic review reported a
trend towards all-cause mortality benefit and reduction in
nephrotoxicity risk in lipid-based formulations of ampho-
tericin B as compared with conventional amphotericin
B,[6] however there was no statistically significant differ-
ence in efficacy (clinical response) between the dosage
formulations. The reasons for discrepancy between all-
cause mortality and efficacy were likely a result of clinical
and methodologic problems. Dosing and duration of
therapy of lipid-based formulations vary widely from
study to study, making results difficult to interpret. Trial
heterogeneity and small sample size also make it difficult
to draw conclusions from comparative studies. An earlier
Table 3: Odds ratios and 95% CrIs for mixed treatment comparisons of confirmed infection studies, all-cause mortality
Treatment Comparison Odds Ratio 95% Credible Interval
Caspofungin vs. Fluconazole 1.34 (0.65, 2.48)
Amphotericin B Deoxycholate vs. Fluconazole 1.14 (0.78, 1.62)
Amphotericin B Liposomal vs. Fluconazole 1.81 (0.71, 3.90)
Voriconazole vs. Fluconazole 0.90 (0.48, 1.53)
Micafungin vs. Fluconazole 1.73 (0.74, 3.49)
Anidulafungin vs. Fluconazole 0.67 (0.36, 1.14)
Itraconazole vs. Fluconazole 0.83 (0.11, 2.94)
Amphotericin B Deoxycholate vs. Caspofungin 0.92 (0.50, 1.54)
Amphotericin B Liposomal vs. Caspofungin 1.35 (0.77, 2.20)
Voriconazole vs. Caspofungin 0.72 (0.33, 1.38)
Micafungin vs. Caspofungin 1.28 (0.86, 1.85)
Anidulafungin vs. Caspofungin 0.56 (0.21, 1.22)
Itraconazole vs. Caspofungin 0.67 (0.08, 2.44)
Amphotericin B Liposomal vs. Amphotericin B Deoxycholate 1.58 (0.68, 3.17)
Voriconazole vs. Amphotericin B Deoxycholate 0.78 (0.49, 1.19)
Micafungin vs. Amphotericin B Deoxycholate 1.51 (0.72, 2.81)
Anidulafungin vs. Amphotericin B Deoxycholate 0.60 (0.29, 1.12)
Itraconazole vs. Amphotericin B Deoxycholate 0.72 (0.10, 2.50)
Voriconazole vs. Amphotericin B Liposomal 0.57 (0.21, 1.26)
Micafungin vs. Amphotericin B Liposomal 0.98 (0.67, 1.38)
Anidulafungin vs. Amphotericin B Liposomal 0.44 (0.13, 1.08)
Itraconazole vs. Amphotericin B Liposomal 0.53 (0.06, 2.02)
Micafungin vs. Voriconazole 2.02 (0.82, 4.18)
Anidulafungin vs. Voriconazole 0.81 (0.33, 1.68)
Itraconazole vs. Voriconazole 0.97 (0.12, 3.46)
Anidulafungin vs. Micafungin 0.45 (0.15, 1.05)
Itraconazole vs. Micafungin 0.54 (0.06, 2.02)
Itraconazole vs. Anidulafungin 1.34 (0.15, 5.05)Annals of Clinical Microbiology and Antimicrobials 2009, 8:23 http://www.ann-clinmicrob.com/content/8/1/23
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systematic review comparing amphotericin dosage forms
found no difference in mortality between lipid and con-
ventional formulations[4]. To our knowledge, no defini-
tive high quality randomized controlled trial comparing
amphotericin B dosage formulations has been published
since the most recent systematic review.
While we did not include pediatric trials in our analysis,
results from a recent systematic review assessing antifun-
gal therapy in children with invasive fungal infections
reported congruent conclusions[25]. Although not a
meta-analysis, the authors' review (including a supple-
mentation with adult studies) led them to conclude that
there was no difference in clinical response between dif-
ferent classes of antifungal agents in the treatment of pro-
longed febrile neutropenia (empiric therapy) or invasive
candidal infection. They did report significant differences
in toxicity (particularly nephrotoxicity) between classes
that favoured azoles and echinocandins over amphoter-
icin B.
In conclusion, our study suggests that azoles and echino-
candins are equally effective interventions for treating
invasive candidiasis and confirms the Infectious Disease
Society of America (IDSA) guidelines[7], that recom-
mends azoles or echinocandins as the first line treatment
for Candida infections. Our analysis found similar within-
class effects. Amphotericin B offers an effective, but more
toxic alternative.
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